Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 663 participants.

Also called NCT05103332

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 663 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05103332
  • EudraCT 2021-003776-13
Other papers using this trial's data
  • Add-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial JAMA, 2025-07-01 DOI, PubMed 40434761, PMC12120674 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Estonia, Germany, Latvia, Lithuania, Poland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05103332. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-05 (actual); primary completion 2023-12-11 (actual). Results posted on 2025-07-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
Acronym
KARDIA-2
Condition
Hypertension
Intervention (Drug)
Indapamide
Intervention (Drug)
Amlodipine
Intervention (Drug)
Olmesartan
Intervention (Drug)
Placebo
Intervention (Drug)
Zilebesiran
Lead sponsor
Alnylam Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct05103332
Content hash
965cfd22b090846859889288f9b130e69c32eac919ee3bd49a0c698a64de46d2